Indian Drugmakers Prepare to Launch Semaglutide Copies as Patent Expires

Novo Nordisk's patent for semaglutide, the active component in the weight-loss medications Ozempic and Wegovy, is set to expire in India on March 20. Bloomberg posted on X that this expiration is paving the way for at least five Indian pharmaceutical companies to introduce more affordable versions of the drug. The move is expected to significantly impact the weight-loss market, offering consumers in India access to cheaper alternatives. As the patent expiration approaches, these companies are gearing up to capitalize on the opportunity, potentially reshaping the landscape of weight-loss treatments in the region.